{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T04:43:27Z","timestamp":1789965807397,"version":"4.0.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1124\/jpet.115.226910","type":"journal-article","created":{"date-parts":[[2015,11,19]],"date-time":"2015-11-19T03:34:06Z","timestamp":1447904046000},"page":"293-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"title":["Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors"],"prefix":"10.1016","volume":"356","author":[{"given":"Andrew","family":"Alt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annapurna","family":"Pendri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Robert L.","family":"Bertekap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Benitex","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Nophsker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin L.","family":"Rockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil T.","family":"Burford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi Shing","family":"Sum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Herbst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Ferrante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Hendricson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ellen","family":"Cvijic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Westphal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martyn","family":"Banks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Litao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert G.","family":"Gentles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Loy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Macor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.115.226910_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0301-0082(02)00079-5","article-title":"Alzheimer\u2019s disease and the basal forebrain cholinergic system: relations to \u03b2-amyloid peptides, cognition, and treatment strategies","volume":"68","author":"Auld","year":"2002","journal-title":"Prog Neurobiol"},{"key":"10.1124\/jpet.115.226910_bib2","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145710001549","article-title":"The M\u2081\/M\u2084 preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia","volume":"14","author":"Barak","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1124\/jpet.115.226910_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archneur.1997.00550160091022","article-title":"Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease","volume":"54","author":"Bodick","year":"1997","journal-title":"Arch Neurol"},{"key":"10.1124\/jpet.115.226910_bib4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/cb800116f","article-title":"G-protein-coupled receptors: from classical modes of modulation to allosteric mechanisms","volume":"3","author":"Bridges","year":"2008","journal-title":"ACS Chem Biol"},{"key":"10.1124\/jpet.115.226910_bib5","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1124\/dmd.113.052084","article-title":"Biotransformation of a novel positive allosteric modulator of metabotropic glutamate receptor subtype 5 contributes to seizure-like adverse events in rats involving a receptor agonism-dependent mechanism","volume":"41","author":"Bridges","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.115.226910_bib6","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/bph.12599","article-title":"Positive allosteric modulators of the \u03bc-opioid receptor: a novel approach for future pain medications","volume":"172","author":"Burford","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.226910_bib7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bcp.2010.12.012","article-title":"Strategies for the identification of allosteric modulators of G-protein-coupled receptors","volume":"81","author":"Burford","year":"2011","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.115.226910_bib8","doi-asserted-by":"crossref","first-page":"4333","DOI":"10.1021\/jm990607u","article-title":"Therapeutic opportunities for muscarinic receptors in the central nervous system","volume":"43","author":"Felder","year":"2000","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.226910_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000113712","article-title":"M1 muscarinic agonists target major hallmarks of Alzheimer\u2019s disease--the pivotal role of brain M1 receptors","volume":"5","author":"Fisher","year":"2008","journal-title":"Neurodegener Dis"},{"key":"10.1124\/jpet.115.226910_bib10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2008.12.044","article-title":"Pharmacological comparison of muscarinic ligands: historical versus more recent muscarinic M1-preferring receptor agonists","volume":"605","author":"Heinrich","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.115.226910_bib11","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.2174\/138161206778522056","article-title":"Muscarinic acetylcholine receptors","volume":"12","author":"Ishii","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.115.226910_bib12","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.104.075887","article-title":"Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats","volume":"312","author":"Jones","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.226910_bib13","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.1021\/jm200400m","article-title":"Discovery of a selective allosteric M1 receptor modulator with suitable development properties based on a quinolizidinone carboxylic acid scaffold","volume":"54","author":"Kuduk","year":"2011","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.226910_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.pharmthera.2007.09.009","article-title":"Muscarinic acetylcholine receptors as CNS drug targets","volume":"117","author":"Langmead","year":"2008","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.115.226910_bib15","doi-asserted-by":"crossref","first-page":"6451","DOI":"10.1016\/j.bmcl.2011.08.084","article-title":"Development of a highly selective, orally bioavailable and CNS penetrant M1 agonist derived from the MLPCN probe ML071","volume":"21","author":"Lebois","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1124\/jpet.115.226910_bib16","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF02740634","article-title":"Nicotinic acetylcholine receptors in health and disease","volume":"15","author":"Lindstrom","year":"1997","journal-title":"Mol Neurobiol"},{"key":"10.1124\/jpet.115.226910_bib17","doi-asserted-by":"crossref","first-page":"15950","DOI":"10.1073\/pnas.0900903106","article-title":"Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation","volume":"106","author":"Ma","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/jpet.115.226910_bib18","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.drudis.2013.09.005","article-title":"Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer\u2019s disease","volume":"18","author":"Melancon","year":"2013","journal-title":"Drug Discov Today"},{"key":"10.1124\/jpet.115.226910_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1527-3458.2003.tb00247.x","article-title":"Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists","volume":"9","author":"Mirza","year":"2003","journal-title":"CNS Drug Rev"},{"key":"10.1124\/jpet.115.226910_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.nbd.2013.09.013","article-title":"Development of allosteric modulators of GPCRs for treatment of CNS disorders","volume":"61","author":"Nickols","year":"2014","journal-title":"Neurobiol Dis"},{"key":"10.1124\/jpet.115.226910_bib21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1124\/mol.111.075184","article-title":"Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function","volume":"81","author":"Noetzel","year":"2012","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.115.226910_bib22","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.biopsych.2012.09.012","article-title":"Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity","volume":"73","author":"Rook","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1124\/jpet.115.226910_bib23","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1021\/jm00090a019","article-title":"Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines","volume":"35","author":"Sauerberg","year":"1992","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.115.226910_bib24","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/10799890600567570","article-title":"Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors","volume":"26","author":"Schwartz","year":"2006","journal-title":"J Recept Signal Transduct Res"},{"key":"10.1124\/jpet.115.226910_bib25","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.tips.2007.06.008","article-title":"Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act?","volume":"28","author":"Schwartz","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/jpet.115.226910_bib26","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0022-3565(25)38667-2","article-title":"Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors","volume":"269","author":"Shannon","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.115.226910_bib27","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia","volume":"165","author":"Shekhar","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1124\/jpet.115.226910_bib28","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00213-014-3813-x","article-title":"Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey","volume":"232","author":"Vardigan","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1124\/jpet.115.226910_bib29","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjp.0702201","article-title":"Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors","volume":"125","author":"Watson","year":"1998","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.226910_bib30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0079-6123(08)62097-X","article-title":"Molecular aspects of muscarinic receptor assembly and function","volume":"109","author":"Wess","year":"1996","journal-title":"Prog Brain Res"},{"key":"10.1124\/jpet.115.226910_bib31","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjp.0702463","article-title":"Functional comparison of muscarinic partial agonists at muscarinic receptor subtypes hM1, hM2, hM3, hM4 and hM5 using microphysiometry","volume":"126","author":"Wood","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.115.226910_bib32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/nrd4052","article-title":"Emerging paradigms in GPCR allostery: implications for drug discovery","volume":"12","author":"Wootten","year":"2013","journal-title":"Nat Rev Drug Discov"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524192324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524192324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.115.226910","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:41:49Z","timestamp":1739994109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524192324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0022356524192324"],"URL":"https:\/\/doi.org\/10.1124\/jpet.115.226910","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence for Classical Cholinergic Toxicity Associated with Selective Activation of M1 Muscarinic Receptors","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.115.226910","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}